MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 4 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $70,000 | +150.0% | 27,190 | +99.2% | 0.00% | – |
| Q1 2020 | $28,000 | -81.5% | 13,650 | -80.5% | 0.00% | – |
| Q4 2019 | $151,000 | +459.3% | 70,061 | +295.1% | 0.00% | – |
| Q3 2019 | $27,000 | -96.5% | 17,731 | -90.6% | 0.00% | – |
| Q2 2019 | $780,000 | +1672.7% | 187,889 | +1679.6% | 0.00% | – |
| Q1 2019 | $44,000 | -72.7% | 10,558 | -81.2% | 0.00% | – |
| Q4 2018 | $161,000 | -72.8% | 56,111 | -5.0% | 0.00% | – |
| Q3 2018 | $591,000 | -9.1% | 59,071 | -35.7% | 0.00% | – |
| Q2 2018 | $650,000 | +1226.5% | 91,866 | +615.2% | 0.00% | – |
| Q1 2018 | $49,000 | +2350.0% | 12,844 | +4487.1% | 0.00% | – |
| Q3 2017 | $2,000 | +100.0% | 280 | -43.3% | 0.00% | – |
| Q2 2017 | $1,000 | -95.5% | 494 | -97.7% | 0.00% | – |
| Q4 2016 | $22,000 | +1000.0% | 21,696 | +1872.4% | 0.00% | – |
| Q3 2016 | $2,000 | +100.0% | 1,100 | -8.3% | 0.00% | – |
| Q2 2016 | $1,000 | -50.0% | 1,200 | +433.3% | 0.00% | – |
| Q4 2015 | $2,000 | -99.6% | 225 | -99.7% | 0.00% | – |
| Q3 2015 | $569,000 | +196.4% | 68,229 | +311.7% | 0.00% | – |
| Q2 2015 | $192,000 | -35.8% | 16,571 | -50.2% | 0.00% | – |
| Q1 2015 | $299,000 | +2890.0% | 33,287 | +2091.4% | 0.00% | – |
| Q3 2014 | $10,000 | – | 1,519 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 1,192,883 | $15,329,000 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 1,431,059 | $18,389,000 | 1.71% |
| Avoro Capital Advisors LLC | 3,000,000 | $38,550,000 | 0.55% |
| Palo Alto Investors LP | 31,330 | $403,000 | 0.02% |